Home > Boards > US Listed > Medical - Healthcare > Entasis Therapeutics Holdings Inc (ETTX)

(ETTX-DD) Low Valuation of $86 Million / STRONG

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BioSpecialist Member Profile
 
Followed By 119
Posts 2,381
Boards Moderated 1
Alias Born 12/27/07
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/27/2021 6:08:14 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 10:08:42 AM
Entasis Therapeutics EPS beats by $0.03 Seeking Alpha - 8/11/2021 4:54:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/11/2021 4:17:28 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/6/2021 6:12:28 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/2/2021 4:40:08 PM
Zai Lab and Entasis complete enrollment in late-stage sulbactam-durlobactam study Seeking Alpha - 7/27/2021 8:16:38 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/20/2021 4:06:57 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 7/19/2021 4:06:32 PM
Entasis Therapeutics shares rise after lining up ETX0462 poster presentation Seeking Alpha - 6/18/2021 8:10:51 AM
Tender Offer Statement by Issuer (sc To-i) Edgar (US Regulatory) - 6/17/2021 4:17:34 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/14/2021 6:00:41 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2021 5:40:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2021 4:06:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2021 2:40:17 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/17/2021 11:03:05 AM
Entasis Therapeutics EPS beats by $0.07 Seeking Alpha - 5/5/2021 5:03:49 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 5/5/2021 4:46:18 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/5/2021 4:32:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2021 4:16:55 PM
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 5/5/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2021 5:01:39 PM
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva GlobeNewswire Inc. - 5/3/2021 4:05:00 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2021 5:19:02 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2021 10:01:50 AM
BioSpecialist   Tuesday, 06/16/20 03:07:48 PM
Re: None
Post # of 15 
(ETTX-DD) Low Valuation of $86 Million / STRONG Cash of $63 Million/ 2 attractive Drugs in late Phase 3 with LARGE market potential with first readout within 6-7 months / Insider & Institutional investors holding most of the shares /Low float stock = $15-20 stock here on this undiscovered biotech gem .GL


Presentation June
https://investors.entasistx.com/static-files/0bf75506-2d54-4b14-896a-6a3d5ed53472

Major Shareholders

Innoviva Inc...14M
Novo Holdings A/S...2.2M
AstraZeneca PLC...2.2M
Clarus Ventures, LLC...1.6M
Pivotal ...1.2M
Sofinnova ...1.2M
Frazier ...1.0M
TPG Capital, L.P...1.0M
Eventide Asset ...879.5K
Granahan ...154.7K





Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences